Perioperative nesiritide versus milrinone in high-risk coronary artery bypass graft patients

被引:15
作者
Brackbill, Marcia L.
Stam, M. Denton
Schuller-Williams, Rebecca V.
Dhavle, Ajil A.
机构
[1] Shenandoah Univ, Bernard J Dunn Sch Pharm, Dept Pharm Practice, Winchester, VA 22601 USA
[2] Winchester Cardiothorac & Vasc Surg PLC, Winchester, VA USA
[3] SureScripts, Clin Practice Integrat, Alexandria, VA USA
关键词
coronary artery bypass graft; milrinone; nesiritide;
D O I
10.1345/APH.1H500
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BACKGROUNDS: Patients with left-ventricular dysfunction have an increased risk of developing heart failure after coronary artery bypass graft (CABG) surgery. Therapies to maintain cardiac output in such patients warrant investigation. Nesiritide is unique among intravenous medications used to manage heart failure. It mediates natriuresis and vasodilation and suppresses the renin-angiotensin-aldersterone axis. Nesiritide may attenuate the body's neuro-hormonal response to myocardial stretch after CABG and provide clinical benefit in the immediate postoperative period. OBJECTIVE: To determine whether perioperative infusion of nesiritide improves clinical outcomes compared with milrinone therapy. METHODS: A prospective, open-label, randomized controlled trial was conducted in 40 consecutive hemodynamically stable patients with ejection fractions 35% of less undergoing CABG surgery. Patients were randomized to receive either an intraoperative bolus of nesiritide or milrinone follwoed by a 24 hr infusion of each agent. Length of postoperative intensive care unit stay was the primary outcome variable evaluated. Incidence of postoperative heart failure, 30 day readmission rates, mortality, and other clinical parameters were also compared. RESULTS: Patients receiving nesiritide had a mean +/- SD postoperative intensive care unit stay of 50.6 +/- 46.8 hours compared with 44.1 +/- 23.5 hours in those receiving milrinone (p = 0.578). Incidence of postoperative heart failure was also not significantly different between the drugs (p = 0.259)/ Thirty day follow-up confirmed no difference in hospital readmission rates between nesiritide and milrinone (p = 0.661). No differences in mortality were observed during hospitalization or 30 days of follow-up. CONCLUSIONS: Nesiritide does not decrease postoperative intensive care unit stay or other clinical parameters compared with milrinone in high-risk patients with hemodynamically stable left-ventricular function undergoing CABG surgery.
引用
收藏
页码:427 / 432
页数:6
相关论文
共 13 条
  • [1] Abraham W T, 1998, J Card Fail, V4, P37, DOI 10.1016/S1071-9164(98)90506-1
  • [2] In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications - An analysis from the Acute Decompensated Heart Failure National Registry (ADHERE)
    Abraham, WT
    Adams, KF
    Fonarow, GC
    Costanzo, MR
    Berkowitz, RL
    LeJemtel, TH
    Cheng, ML
    Wynne, J
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 46 (01) : 57 - 64
  • [3] Outcomes associated with vasoactive therapy in patients with acute decompensated heart failure
    Arnold, Lindsay M.
    Crouch, Michael A.
    Carroll, Norman V.
    Oinonen, Michael J.
    [J]. PHARMACOTHERAPY, 2006, 26 (08): : 1078 - 1085
  • [4] Natriuretic peptides in the pathophysiology of congestive heart failure
    Chen H.H.
    Burnett Jr. J.C.
    [J]. Current Cardiology Reports, 2000, 2 (3) : 198 - 205
  • [5] Heart failure etiology and response to milrinone in decompensated heart failure - Results from the OPTIME-CHF study
    Felker, GM
    Benza, RL
    Chandler, AB
    Leimberger, JD
    Cuffe, MS
    Califf, RM
    Gheorghiade, M
    O'Connor, CM
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (06) : 997 - 1003
  • [6] Predictors of readmission for complications of coronary artery bypass graft surgery
    Hannan, EL
    Racz, MJ
    Walford, G
    Ryan, TJ
    Isom, OW
    Bennett, E
    Jones, RH
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (06): : 773 - 780
  • [7] HEBELER RF, 2006, 7 SCI FOR QUAL CAR O
  • [8] LUBER JM, 2006, HEART FAIL SOC AM 20
  • [9] Nesiritide (BNP) in the management of postoperative cardiac patients
    Moazami, N
    Damiano, RJ
    Bailey, MS
    Hess, RL
    Lawton, JS
    Moon, MR
    Pasque, MK
    [J]. ANNALS OF THORACIC SURGERY, 2003, 75 (06) : 1974 - 1976
  • [10] Continuous intravenous dobutamine is associated with an increased risk of death in patients advanced heart failure: Insights from the Flolan International Randomized Survival Trial (FIRST)
    O'Connor, CM
    Gattis, WA
    Uretsky, BF
    Adams, KF
    McNulty, SE
    Grossman, SH
    McKenna, WJ
    Zannad, F
    Swedberg, K
    Gheorghiada, M
    Califf, RM
    [J]. AMERICAN HEART JOURNAL, 1999, 138 (01) : 78 - 86